Tempo Pharmaceuticals is developing a pipeline of products within multiple therapeutic areas based on its nanoparticle-based technology licensed from the Massachusetts Institute of Technology. The most advanced product opportunities are in oncology.
The emerging field of Nanopharmaceuticals has the potential to transform drug therapy and become one of the most important advancements in technology over the next decade. Intelligently engineered drugs that utilize nanotechnology have the potential for much improved properties, including efficacy and safety.
Nanopharmaceuticals consist of ultra-small particles measured in nanometers (a nanometer is one billionth of a meter). These particles can be designed to target diseased tissues, to control the release of therapeutic concentrations over a prolonged period of time, and to enable alternative routes of administration.
The Need for a New Approach to Cancer
Oncologists have available to them a number of extremely potent anti-tumor agents. These drugs are often capable of killing tumor cells in vitro and achieving cures in animals. However, large numbers of cancer patients are not able to be cured by these existing therapies. Despite this fact, current research and development efforts throughout the industry are primarily directed to creating completely new agents, most of which will not have the potent activity of the best agents that are already available.
Tempo is focused on solving the fundamental problems associated with why cancer drugs do not work optimally in people using its proprietary nanoparticle-based intelligently designed drugs.
The Nanocell Solution
The Company utilizes its proprietary Nanocell technology to develop multi-compartmental, nanoparticle-based therapeutics in which two drugs with varied release rates are packaged within a single nanoparticle. This approach allows for sequential delivery of the drugs, optimizing the location, rate of release and synergistic effect of the two therapies while minimizing toxicities.